migvax

MigVax receives funding award from CEPI to develop ‘variant-proof’ COVID-19 vaccines

04-11-2021
CEPI
MigVax receives funding award from CEPI to develop ‘variant-proof’ COVID-19 vaccines
We are honored to be one of the first two projects to receive funding from CEPI’s visionary program aimed at accelerating the development of broadly protective vaccines against coronaviruses and their variants

WARNING!! Fraud Notice – Covid-19 Product

26-05-2020
Migal Galilee Research Institute Ltd., Migvax Ltd.
WARNING!! Fraud Notice – Covid-19 Product
We have just been made aware that a fake pharmaceutical product allegedly for use in connection with COVID-19 is fraudulently being advertised and apparently sold in South America with the logo of Migal and with the following wording: " COVID-19 vaccine tracker. Cutting edge Israeli Biotech innovating coronavirus immunotherapy treatments." A photograph appears below.